Navigation Links
Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Date:3/16/2011

Nitroglycerin produces dose-related headaches, which may be severe. Tolerance to headaches occurs. The most common adverse reactions are headache, flushing, hypotension and syncope.

[Web version]

Click here for full Prescribing Information

[Email version]

Please see attached full Prescribing Information

*Priming NitroMist: After receiving a new prescription or refill, patients should remove the plastic cap, place forefinger on actuator button, and press 10 times. NitroMist is now primed for 6 weeks and ready to use. If not used for more than 6 weeks, the NitroMist bottle can be adequately reprimed with 2 sprays.

NitroMist is a registered trademark of Novadel Pharma, Inc., used by permission.

For more information about NitroMist please visit www.nitromist.com

About AkrimaxAkrimax Pharmaceuticals, LLC is a privately held, fully integrated next-generation specialty pharmaceutical company that acquires, markets, and develops products to address disease states related to cardiovascular, metabolic and endocrine diseases. Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products.

For more information on NitroMist or other Akrimax products, please contact

Jim Misner or Aleen Hosdaghian of Akrimax Pharmaceuticals, LLC, 908.372.0500.

To learn more about Akrimax, please visit www.akrimax.com

References: 1. Heart disease and stroke statistics—2010 update. American Heart Association. 2010: pp1-36. 2. Coronary artery disease. http://adam.about.com/reports/Coronary-artery-disease.htm. Updated 5/15/200
'/>"/>

SOURCE Akrimax Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 This report analyzes ... by the following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, ... for the US Canada, Japan , ... Latin America , and Rest of World. Annual ... 2018. Also, a six-year historic analysis is provided for these ...
(Date:9/30/2014)... MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Scientific Officer, will present at the Stem Cell Meeting ... October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... Sept. 30, 2014 STUDY OBJECTIVES ... is to provide an overview of the current ... protein drugs/therapeutics. The key objective is to present ... drugs as an important tool in the treatment ... and future strategies within the protein therapeutics market, ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... , DURHAM, N.C., Sept. 8 ... formally notified Vatea Fund of the company,s achievement of a milestone ... September 1, 2009. The milestone is a Clinical Trial for Oxycyte ... With the achievement of the milestone, the agreement calls for ...
... BOZEMAN, Mont., Sept 8 LigoCyte Pharmaceuticals, Inc. ... clinical trial of its norovirus vaccine. The Phase I/II ... nasally-delivered, dry powder vaccine in healthy adults. The study will ... by including a live virus challenge of subjects that have ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 2LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 3
(Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... October is Breast Cancer Awareness,Month, and while awareness ... an,all-time high, the percentage of women receiving regular ... Disease Control and,Prevention. Women should know that emerging ... maintain their long-term breast health. Listen to ...
... blood leaving the liver during chemotherapy could prolong the lives ... procedure allows massive doses of chemotherapy drugs to reach the ... of the body. , The regime involves injecting the drug ... divert the blood leaving it. This blood is then filtered ...
... Germany, Sept. 26 Ziehm,Imaging, a provider ... a manufacturer of software-driven systems for targeted,less-invasive ... agreement for the integration of mobile 3D ... 2002, Ziehm Imaging and BrainLAB jointly pioneered ...
... Small Disadvantaged ... Businesses, ... and GlaxoSmithKline (NYSE: GSK ) today announced,the results of a ... disadvantaged businesses (SDBs). Rep. Kendrick B. Meek (D-Fla.), chairman of ...
... at ADA,s Annual,Meeting Here, SAN FRANCISCO, Sept. 26 ... including heart,problems, diabetes and pneumonia make it even more ... a lifetime., According to a recent report from ... keeping their natural teeth longer well beyond,the age of ...
... BIRMINGHAM, Ala., Sept. 26 HealthSouth,Corporation (NYSE: HLS ... a regular quarterly dividend of $16.25 per share on ... October 15,2007, to holders of record on October 1, ... largest provider of inpatient,rehabilitation services. Operating in 27 states ...
Cached Medicine News:Health News:'Re-plumbing' liver helps beat cancer 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 3Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 2Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 3Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 2Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
OmoTrain is a unique support for the shoulder that promotes mobility and limits rotation....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... someone suffers an episode of acute low ... The QuikDraw PRO quickly restores functional mobility ... relief.,With just a few sizes that correspond ... the QuikDraw PRO will reduce inventory requirements ...
Medicine Products: